The IACT project (FP7) website is up and running


LeadArtis is a partner of the IACT (Immunostimulatory Agonist Antibodies for Cancer Therapy) 6.9M€ funding consortium (Project Number: 602262). The IACT is an interdisciplinary platform that involves a total of 10 partners with long-standing expertise in agonist immunostimulatory antibodies (IS-Abs), from research institutions and small-medium enterprises (SEM) located in five European countries (Germany, Italy, Spain, Sweden and United Kingdom). Recently the website regarding this project ( been elaborated and is now ready for its visualization. We find the information included in the site relevant and a good basis to start interacting with other immunotherapy-oriented EU-projects, companies and research groups.

The IACT program aims to translate the agonist IS-Ab concept into clinical treatments. Two ongoing clinical trials are pivotal to bring forward the pre-clinical Proof of Concept in which striking therapeutic impact with agonist IS-Abs has been obtained. A parallel SME-driven effort will aim at the development of 2nd generation agonist IS-Abs with superior therapeutic index. In this regard, LeadArtis will apply its TrimerbodyTM technology to the development of optimized agonist IS-Abs and for strengthening the IACT agonist IS-Ab pipeline.

Latest News

Leadartis successfully accomplishes the TERET project

Leadartis is proud to announce the successful conclusion of the TERET (New Treatments for...

LeadArtis participates in the third Immunostimulatory Agonist Antibodies for Cancer Therapy (IACT) meeting

The third IACT review meeting took place on October 25-26, 2016 in Frankfurt, Germany. LeadArtis...

Leadartis to present at BioSpain 2016 in Bilbao

Leadartis will participate in BioSpain 2016 to be held...